Vera Therapeutics Inc
NASDAQ:VERA
Intrinsic Value
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of VERA.
Vera Therapeutics Inc's market capitalization is 2.1B USD.
VERA stock price is 38 USD.
VERA.
VERA. Open DCF Valuation
VERA. Open Relative Valuation
VERA has upside potential of 31% compared to the average analyst price target.
Open Wall St Estimates
VERA has negative Free Cash Flow for the last twelve months.
VERA's Altman Z-Score is equal to 2.35.
VERA's ROE (Return on Equity) has significantly increased in the last 3 years from -120% to -108%, and is approaching profitability.
VERA has negative Operating Income for the last twelve months.
VERA has negative Net Income for the last twelve months.
VERA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -5 721% to -2 425%, and is approaching profitability.
VERA's ROE (Return on Equity) for the past 12 months is negative and is equal to -108%.
VERA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 425%.
VERA's long-term assets (176m USD) exceed its long-term liabilties (74m USD).
VERA's D/E (Debt to Equity) is very low and is equal to 0.49.
VERA has negative Net Debt. This means that the company has more cash and short-term investments (161m USD) than debt (50m USD).
VERA has negative three-year average ROE (Return on Equity): -73%. The company is not efficient at transforming stockholders' equity into net income.
VERA has negative three-year average ROIC (Return on Invested Capital): -1 762%. The company is not efficient at using invested capital to generate operating income.
VERA's short-term assets (172m USD) exceed its short-term liabilties (22m USD).
VERA doesn't generate enough operating income (-102m USD) to safely cover interest payments on its debt (3m USD).
Fundamental Analysis
Vera Therapeutics Inc
Balance Sheet Decomposition
Vera Therapeutics Inc
| Current Assets | 172m |
| Cash & Short-Term Investments | 160.7m |
| Other Current Assets | 11.3m |
| Non-Current Assets | 3.5m |
| Long-Term Investments | 11k |
| PP&E | 2.9m |
| Other Non-Current Assets | 563k |
| Current Liabilities | 22.3m |
| Accounts Payable | 11.1m |
| Accrued Liabilities | 11.2m |
| Non-Current Liabilities | 51.6m |
| Long-Term Debt | 49.9m |
| Other Non-Current Liabilities | 1.7m |
Earnings Waterfall
Vera Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-102m
USD
|
|
Operating Income
|
-102m
USD
|
|
Other Expenses
|
6m
USD
|
|
Net Income
|
-96m
USD
|
Free Cash Flow Analysis
Vera Therapeutics Inc
What is Free Cash Flow?
VERA Profitability Score
Profitability Due Diligence
Vera Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Vera Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
VERA Solvency Score
Solvency Due Diligence
Vera Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Vera Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VERA Price Targets Summary
Vera Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
VERA
is 49.85 USD
with a low forecast of 25.25 USD and a high forecast of 63 USD.
Ownership
VERA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
VERA Price
Vera Therapeutics Inc
| Average Annual Return | 54.61% |
| Standard Deviation of Annual Returns | 126.42% |
| Max Drawdown | -85% |
| Market Capitalization | 2.1B USD |
| Shares Outstanding | 54 452 000 |
| Percentage of Shares Shorted | 17.2% |
Company Profile
Vera Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 17 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The company is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus.
You don't have any saved screeners yet
